anti tnbc agent 1

anti-TNBC agent-1 is a highly effective compound specifically targeting and combating triple-negative breast cancer (TNBC), demonstrating remarkable potency against various breast cancer cell types with IC50 values ranging from 0.20 μM to 0.27 μM. Its mechanism of action involves inducing apoptosis in SUM-159 cells through the mitochondria pathway and causing G1 phase arrest in these cells.

Anti-TNBC agent-3 (compound 3g) is a compound that induces apoptosis and possesses anti-cancer cell proliferation properties. It effectively inhibits tumor growth and metastasis in xenograft models of triple-negative breast cancer (TNBC) [1].

Anti-TNBC agent-2 (3j), a purine derivative, acts as an anti-triple negative breast cancer (TNBC) therapeutic. It promotes apoptosis in MDA-MB-231 cells, while also inhibiting their migration and angiogenesis. Moreover, anti-TNBC agent-2 suppresses tumor growth and metastasis, and downregulates Ki67 and CD31 protein expression in TNBC xenograft models. It may be utilized for TNBC research [1].